SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-025725
Filing Date
2022-07-11
Accepted
2022-07-11 17:02:16
Documents
14
Period of Report
2022-07-07
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20004306x7_8k.htm   iXBRL 8-K 39423
2 EXHIBIT 3.1 ny20004306x7_ex3-1.htm EX-3.1 10843
3 EXHIBIT 3.2 ny20004306x7_ex3-2.htm EX-3.2 65892
  Complete submission text file 0001140361-22-025725.txt   280562

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ettx-20220707.xsd EX-101.SCH 3926
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ettx-20220707_lab.xml EX-101.LAB 24033
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ettx-20220707_pre.xml EX-101.PRE 17060
8 EXTRACTED XBRL INSTANCE DOCUMENT ny20004306x7_8k_htm.xml XML 4391
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38670 | Film No.: 221077484
SIC: 2834 Pharmaceutical Preparations